Tumor mutation burden is the relative number of mutations in a given tumor tissue.[81] If there are more non-synonymous mutations in the tumor, more neoantigens appear, and the PD-1/PD-L1 axis is involved in blocking the immune response, thus affecting the response of tumor cells to ICIs. This evidence concerns the gene CD274 and neoplasm.